LivaNova Q2 revenue $318.6M (+8.4%), adj. EPS $0.93; raises FY outlook

LivaNova PLC

2024-Q2 EPS reported -$0.47 revenue$613,487,000

Q2 revenue $318.6M, up 8.4% reported and 9.6% constant-currency; ex-ACS wind down, constant-currency growth 10.8%.
GAAP diluted EPS $0.30; adjusted diluted EPS $0.93.
Raised full-year 2024 revenue and adjusted diluted EPS guidance.
Franco Poletti named President of Cardiopulmonary Business Unit, effective August 1, 2024.
Plans to pursue CMS coverage for VNS Therapy in RECOVER patient population; reducing 2025 investment in difficult-to-treat depression.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.